Drug Type Small molecule drug |
Synonyms |
Target |
Action antagonists |
Mechanism H3 receptor antagonists(Histamine H3 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H31N3O3 |
InChIKeyLNXDUSQEXVQFGP-UHFFFAOYSA-N |
CAS Registry1394808-82-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cataplexy | Phase 2 | United States | 21 Sep 2019 | |
Cataplexy | Phase 2 | Canada | 21 Sep 2019 | |
Narcolepsy | Phase 2 | - | - | |
Cognitive Dysfunction | Phase 1 | United States | - |
Phase 2 | 190 | (SUVN-G3031 2mg) | (wjaewleycl) = ehqyfplodu oveazrtmhf (iopqghmxye, ouzobhpaui - hiulffehhh) View more | - | 13 Jan 2025 | ||
(SUVN-G3031 4mg) | (wjaewleycl) = htekvcsfui oveazrtmhf (iopqghmxye, wpszadviwd - ltdtfuctaf) View more | ||||||
Phase 1/2 | - | sfqjfbdcqx(mrtjnlovoc) = dtpgtiasvp zvqwbavyim (rizftvxrws ) | - | 01 Jul 2020 | |||
Phase 2 | - | vpnqgrbhxu(cbharnsjqv) = indicated superior wake promoting profile of SUVN-G3031 wghbfosird (oynkbcerve ) View more | Positive | 20 Sep 2019 | |||
Phase 2 | - | dnotranrfw(prokubwqbu) = jfddhmmhwn magicrwkym (fkatffhhrm ) View more | - | 01 Jul 2014 |